Cover Image
市場調查報告書

青光眼:現在·未來市場參與企業

Glaucoma - Current and Future Players

出版商 GlobalData 商品編碼 371774
出版日期 內容資訊 英文 95 Pages
訂單完成後即時交付
價格
Back to Top
青光眼:現在·未來市場參與企業 Glaucoma - Current and Future Players
出版日期: 2015年05月11日 內容資訊: 英文 95 Pages
簡介

本報告提供全球青光眼治療藥的市場上現有/新加入企業相關分析,提供您整體市場的未來展望和促進·阻礙因素,現在·未來的競爭趨勢,主要企業簡介(企業概要,企業發展,財務狀況,SWOT分析)等調查。

第1章 目錄

第2章 簡介

  • 分析的背景情況
  • 相關報告
  • 近日出版的相關報告

第3章 市場預測

  • 全球市場
    • 市場預測
    • 促進·阻礙因素:全球市場課題

第4章 現在·未來市場參與企業

  • 概要
  • 企業策略的趨勢
  • 企業簡介
    • Pfizer
    • Alcon
    • Allergan
    • 參天製藥
    • Aerie Pharmaceuticals
    • Inotek Pharmaceuticals
    • Bausch & Lomb
    • 興和
    • 大塚製藥

第5章 附錄

圖表一覽

目錄
Product Code: GDHC1055FPR

GlobalData has released its pharma report, "Glaucoma - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Glaucoma Market. The report identifies and analyses the key companies shaping and driving the global Glaucoma market. The report provides insight into the competitive Glaucoma landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Glaucoma
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of Glaucoma sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving Glaucoma market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global Glaucoma market landscape? Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers and Barriers - Global Issues

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3. Company Profiles
    • 4.3.1. Pfizer
    • 4.3.2. Alcon
    • 4.3.3. Allergan
    • 4.3.4. Santen
    • 4.3.5. Aerie Pharmaceuticals
    • 4.3.6. Inotek Pharmaceuticals
    • 4.3.7. Bausch & Lomb
    • 4.3.8. Kowa Company
    • 4.3.9. Otsuka Pharmaceutical

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Percent Drug-Treated Patients
    • 5.4.2. Drugs Included in Each Therapeutic Class
    • 5.4.3. Launch and Patent Expiry Dates
    • 5.4.4. General Pricing Assumptions
    • 5.4.5. Individual Drug Assumptions
    • 5.4.6. Pricing of Pipeline Agents
  • 5.5. Primary Research - KOLs Interviewed for this Report
  • 5.6. Primary Research - High-prescriber Survey
  • 5.7. About the Authors
    • 5.7.1. Analyst
    • 5.7.2. Therapy Area Director
    • 5.7.3. Epidemiologist
    • 5.7.4. Global Head of Healthcare
  • 5.8. About GlobalData
  • 5.9. Disclaimer

List of Tables

  • Table 1: Global Sales Forecast ($m) for Glaucoma, 2013-2023
  • Table 2: Glaucoma Market - Drivers and Barriers, 2013-2023
  • Table 3: Key Companies in the Glaucoma Market in the 7MM, 2014
  • Table 4: Pfizer's Glaucoma Portfolio Assessment, 2014
  • Table 5: Alcon's Glaucoma Portfolio Assessment, 2014
  • Table 6: Allergan's Glaucoma Portfolio Assessment, 2014
  • Table 7: Santen's Glaucoma Portfolio Assessment, 2014
  • Table 8: Aerie's Glaucoma Portfolio Assessment, 2014
  • Table 9: Inotek's Glaucoma Portfolio Assessment, 2014
  • Table 10: Baush & Lomb/Valeant's Glaucoma Portfolio Assessment, 2014
  • Table 11: Kowa's Glaucoma Portfolio Assessment, 2014
  • Table 12: Otsuka's Glaucoma Portfolio Assessment, 2014
  • Table 13: Key Launch Dates
  • Table 14: Key Patent Expiries
  • Table 15: Surveyed High-Prescribing Physicians (Non-KOLs), by Country

List of Figures

  • Figure 1: Global Sales for Glaucoma by Region, 2013-2023
  • Figure 2: Drug Sales by Class for Glaucoma, 2013 and 2023
  • Figure 3: Global Drug Sales by Class for Glaucoma, 2013-2023
  • Figure 4: Global Sales of Branded Products for Glaucoma by Company, 2013-2023
  • Figure 5: Company Portfolio Gap Analysis in Glaucoma, 2013-2023
Back to Top